Physician profile
David M Lee
NPI 1225276652
$5,361.23
in general payments reported to CMS, 2019-2025
34 companies · $890 in 2025
The $890 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $791 · 2021: $815 · 2022: $685 · 2023: $295 · 2024: $465 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,560.76 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,064.75 | 2019-2025 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $576.57 | 2020-2025 | Evoque, Konect Resilia |
| Janssen Pharmaceuticals, INC | $453.52 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $355.83 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $335.12 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $289.34 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $280.48 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $223.24 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $207.98 | 2022-2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.61 | 2019-2022 | |
| Abbott Laboratories | $182.66 | 2019-2022 | |
| Medtronic, INC. | $173.09 | 2024 | Corevalve Evolut R |
| Amarin Pharma, INC. | $169.66 | 2019-2021 | |
| Amgen INC. | $167.50 | 2019-2020 | |
| Esperion Therapeutics, INC. | $112.28 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $95.97 | 2020-2022 | |
| Pfizer INC. | $91.86 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.65 | 2019-2021 | |
| Abiomed | $53.68 | 2023-2024 | Impella |
| Xeris Pharmaceuticals, INC. | $35.57 | 2021 | |
| Cardinal Health 200 LLC | $28.46 | 2019 | |
| United Therapeutics Corporation | $23.22 | 2022 | |
| Aegerion Pharmaceuticals, INC. | $18.85 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $18.80 | 2021 | |
| Kestra Medical Technology Services, INC. | $17.87 | 2025 | Assure Wcd |
| Lilly USA, LLC | $17.39 | 2019 | |
| Gilead Sciences, INC. | $15.98 | 2019 | |
| Amryt Pharma Holdings LTD | $15.13 | 2021 | |
| Astellas Pharma US INC | $14.99 | 2019 | |
| Irhythm Technologies, INC. | $14.35 | 2021 | |
| Tactile Systems Technology INC | $13.26 | 2020 | |
| Boston Scientific Corporation | $13.21 | 2022 | |
| Infobionic, INC | $11.36 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.